1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
NAPSRx Logo

AstraZeneca will acquire Almirall's respiratory drug portfolio

AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.

 
PRLog - Jul. 31, 2014 - WASHINGTON, D.C. -- AstraZeneca has announced its plans to enter into an agreement with Almirall to transfer over its respiratory franchise for an initial cost consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.

AstraZeneca will own the rights to develop and commercialize Almirall’s respiratory business. This of course includes the rights to revenues from Almirall’s present partnerships and the company’s current pipeline of investigational novel therapies.

Almirall’s respiratory portfolio and franchise includes: Eklira® (aclidinium); LAS40464, the combination of aclidinium with formoterol which has been filed for registration in the EU and is being developed in the US; LAS100977 (abediterol), a once-daily long-acting beta2-agonist (LABA) in Phase II; an M3 antagonist beta2-agonist (MABA) platform in pre-clinical development (LAS191351, LAS194871) and Phase I (LAS190792); and multiple pre-clinical programmes.

This acquisition will further propel AstraZeneca’s presence in the respiratory market adding to their successful product pipeline which includes: Symbicort® and Pulmicort®, as well as the company’s investigational medicines in development. AstraZeneca will receive immediate access to on market revenue which will boost the company’s overall revenue growth.  Pascal Soriot, Chief Executive Officer of AstraZeneca said: “Our agreement with Almirall brings strategic and long-term value to AstraZeneca’s strong respiratory franchise, one of our key growth platforms. We will benefit from immediate and growing product revenues which we anticipate will be rapidly accretive to earnings. Chronic respiratory disease affects hundreds of millions of people around the world. By combining our innovative portfolios and leveraging AstraZeneca’s global scientific and commercial capabilities, we will strengthen our ability to address the entire spectrum of care in asthma and COPD. I very much look forward to welcoming the Almirall people to our company.”

Jorge Gallardo, President of Almirall added: “This important agreement allows us to better develop our assets and expertise in respiratory with AstraZeneca, an experienced player in this therapeutic area. It also allows us to better balance the costs, risks and returns of the respiratory business while retaining an important economic interest in its future success. All this constitutes a very solid baseline to move more aggressively in specialty areas and particularly towards becoming a global dermatology player. R&D will remain a key part of Almirall’s business going forward and hopefully a significant long-term growth driver."

The anticipated closing of this transaction is expected to be complete by the end of 2014.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.

Contact
NAPSRx
1-800-284-1060
***@napsronline.org

--- End ---

Click to Share

Contact Email:
***@napsronline.org Email Verified
Source:NAPSRx
City/Town:Washington - District of Columbia - United States
Industry:Health, Marketing
Tags:napsr, napsrx, cnpr certification, naprx, pharmaceutical sales
Shortcut:prlog.org/12354591
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share